Free Newsletter
FDA won't deliver on social media rules
Once again, the FDA fails to meet a deadline. This time, it's the promised guidelines on using the Internet and social media for marketing--the guidelines that drugmakers have been anxiously awaiting...even demanding--for years now.
The agency gathered suggestions this year, including a two-day hearing during which everyone from Google to Novartis presented their hopes and fears about regulatory oversight of pharma's online activities. The FDA pledged to deliver draft guidelines by year's end. As Pharmalot reports, that's not going to happen, the agency says.
Apparently, the world of online and social media has proven too broad a target. The agency has broken that world into bite-sized topics, such as "fulfilling regulatory requirements when using tools associated with space limitations" and "online communications for which manufacturers are accountable" and "responding to unsolicited requests." And it plans to release one draft guidance that deals with at least one of these topics during the first quarter of next year.
- read the Pharmalot post
Related Articles:
As pharma awaits FDA rules, marketing happens
Status update: Pharma skeptical of social media
Law and order on the social media frontier
AZ pitches social-media rules to FDA
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: